Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.25 USD
Change Today 0.00 / 0.00%
Volume 0.0
KURU On Other Exchanges
As of 8:10 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

kun run biotechnology inc (KURU) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/30/15 - $0.25
52 Week Low
06/30/15 - $0.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

kun run biotechnology inc (KURU) Related Businessweek News

No Related Businessweek News Found

kun run biotechnology inc (KURU) Details

Kun Run Biotechnology, Inc., a bio-pharmaceutical company, together with its subsidiaries, engages in the development, manufacture, marketing, and sale of polypeptide medicines and small molecule drugs. Its principal products are prescription polypeptide drugs used to treat immune system malfunction and hyper function. The company manufactures and markets prescription polypeptide drugs, including Thymopentin, a two-phase immunostimulant used for treating tumor and hepatitis; and Somatostatin, a synthetic cyclic 14-amino acid peptide to treat acute severe pancreatitis, upper gastrointestinal hemorrhages, pancreatic fistulas, intestinal fistulas, and biliary fistulas. Its products also include Thymosin Alpha 1 for treating chronic hepatitis B when used alone or in combination with interferon, as well as for treating hepatitis C, malignant tumors, melanoma, and HIV/AIDS; and Desmopressin Acetate, a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin to treat nocturnal enuresis, central diabetes insipidus, polyuria, polydipsia mild, and moderate forms of hemophilia A, as well as used before surgeries to prevent bleeding. The company offers its peptide products in various forms, including injections, capsules, and pills. In addition, it provides approximately 11 new products in various stages from per-clinical research to State Food and Drug Administration of China application, which address various diseases, including diabetes, coagulant disease, hydrocephalus, and tumor. The company sells its products through pharmaceutical distribution companies to hospitals and medical institutions in the People’s Republic of China. Kun Run Biotechnology is headquartered in Haikou, the People’s Republic of China.

149 Employees
Last Reported Date: 03/30/10
Founded in 2006

kun run biotechnology inc (KURU) Top Compensated Officers

Chief Executive Officer and General Manager
Total Annual Compensation: --
Principal Financial Officer and Chief Account...
Total Annual Compensation: --
Chief Quality Control Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KURU:US $0.25 USD 0.00

KURU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KURU.
View Industry Companies

Industry Analysis


Industry Average

Valuation KURU Industry Range
Price/Earnings 1.5x
Price/Sales 0.6x
Price/Book 0.2x
Price/Cash Flow 1.4x
TEV/Sales 0.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KUN RUN BIOTECHNOLOGY INC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at